Sandoz Group AG | WebDisclosure

Basculer en Français

10018	Companies
203427	Keywords
133902	Articles
107960	Press releases

Home
Companies
Sandoz Group AG

BRIEF

published on 02/23/2026 at 11:05, 16 days ago

Sandoz obtient l'approbation de l'UE pour Ranluspec, renforçant ainsi sa position sur le marché des biosimilaires.

Biosimilaires Ophtalmologie Commission Européenne Stratégie Sandoz Approbation Ranluspec
PRESS RELEASE

published on 02/23/2026 at 11:00, 16 days ago

Sandoz confirms European Commission approval for Ranluspec® (ranibizumab), further strengthening overall biosimilars leadership and position in ophthalmology
Sandoz confirms European Commission approval for Ranluspec®, strengthening biosimilars leadership in ophthalmology. Launch planned for second half of 2026

Biosimilars Ophthalmology Sandoz European Commission Approval Ranluspec
BRIEF

published on 02/18/2026 at 07:05, 21 days 4 hours ago

Sandoz étend l'indication d'Enzeevu® grâce à l'approbation de la FDA pour les affections rétiniennes

Approbation De La FDA Biosimilaires Sandoz Enzeevu Indications Rétiniennes
BRIEF

published on 02/18/2026 at 07:05, 21 days 4 hours ago

Sandoz Expands Enzeevu® Label with FDA Approval for Retinal Indications

FDA Approval Biosimilars Sandoz Enzeevu Retinal Indications
PRESS RELEASE

published on 02/18/2026 at 07:00, 21 days 4 hours ago

Sandoz receives US FDA approval to expand Enzeevu® (aflibercept-abzv) label for multiple retinal indications
Sandoz receives US FDA approval to expand Enzeevu® (aflibercept-abzv) label to include multiple retinal indications, offering new treatment options for retinal diseases

FDA Approval Vision Care Sandoz Enzeevu Retinal Indications
BRIEF

published on 01/14/2026 at 12:05, 1 month 27 days ago

Sandoz obtient l'approbation de l'UE pour Ondibta® dans le traitement du diabète

Biosimilaires Traitement Du Diabète Commission Européenne Approbation Ondibta® Stratégie Sandoz
BRIEF

published on 01/14/2026 at 12:05, 1 month 27 days ago

Sandoz Secures EU Approval for Ondibta® in Diabetes Treatment

European Commission Biosimilars Diabetes Treatment Ondibta® Approval Sandoz Strategy
PRESS RELEASE

published on 01/14/2026 at 12:00, 1 month 27 days ago

Sandoz confirms European Commission approval of Ondibta® (insulin glargine), strengthening overall biosimilars leadership and position in diabetes
Sandoz confirms European Commission approval of Ondibta® (insulin glargine), strengthening overall biosimilars leadership and position in diabetes. Expected launch by early 2027

Diabetes European Commission Biosimilars Sandoz Ondibta
BRIEF

published on 01/12/2026 at 15:05, 1 month 29 days ago

Sandoz dévoile sa stratégie pour une « décennie d'or » des médicaments abordables

Stratégie De Marché Biosimilaires Groupe Sandoz AG Médicaments Abordables Décennie Dorée
BRIEF

published on 01/12/2026 at 15:05, 1 month 29 days ago

Sandoz Unveils Strategy for 'Golden Decade' of Affordable Medicines

Market Strategy Biosimilars Sandoz Group AG Golden Decade Affordable Medicines

Accesswire

Published on 03/11/2026 at 09:00, 2 hours 53 minutes ago

QNX Expands Free Online Learning Platform to Accelerate Global Developer Readiness and Support the Growing Adoption of QNX Software
Published on 03/11/2026 at 07:05, 4 hours 48 minutes ago

Tocvan Announces Appointment of Darin Wagner as Special Advisor
Published on 03/11/2026 at 00:15, 11 hours 38 minutes ago

Zeus North America Mining Corp. Announces Closing of First Tranche of Private Placement
Published on 03/10/2026 at 22:40, 13 hours 13 minutes ago

Ur-Energy Updates Lost Creek Property Technical Report Summary Estimating an Extended Mine Life and Increase in Net Cash Flow
Published on 03/10/2026 at 22:30, 13 hours 23 minutes ago

Ur-Energy Reports Year-End 2025 Results and Announces Conference Call and Webcast

View all ACCESSWIRE

EQS Group

Published on 03/11/2026 at 11:46, 6 minutes ago

EQS-Adhoc: BayWa AG: Adjustment of the restructuring concept necessary due to new planning by BayWa r.e., negotiations with financing partners ongoing
Published on 03/11/2026 at 11:43, 10 minutes ago

BROXO Unveils Brand Refresh, reinforcing over 100 Years of expertise in Water Treatment Salt
Published on 03/11/2026 at 10:07, 1 hour 45 minutes ago

Nasdaq Study: Growth in International Financial Crime Continues to Accelerate – Germany is EU capital for romance and impersonation scams
Published on 03/11/2026 at 09:24, 2 hours 29 minutes ago

Deutsche Beteiligungs AG continues value realisation with successful disposal of Kraft & Bauer investment out of DBAG Fund VII to Syngroh Capital, the investment entity of the Grohe family
Published on 03/11/2026 at 09:22, 2 hours 31 minutes ago

Stepstone long-term analysis: Soft skills required in almost every second job

Les Echos

Published on 03/11/2026 at 10:02, 1 hour 51 minutes ago

WEB SA - MODIFICATION AGENDA FINANCIER EXERCICE 2025
Published on 03/11/2026 at 08:00, 3 hours 53 minutes ago

BIOPHYTIS ANNOUNCES COMPLETION OF OVER €2.0 MILLION CAPITAL INCREASE AND THE REPAYMENT OF ALL VARIABLE PRICE CONVERTIBLE DEBT
Published on 03/11/2026 at 08:00, 3 hours 53 minutes ago

BIOPHYTIS ANNONCE LA REALISATION D’UNE LEVEE DE FONDS DE PLUS DE 2 MILLIONS D’EUROS ET LE REMBOURSEMENT DE L’INTEGRALITE DE SA DETTE CONVERTIBLE A PRIX VARIABLE
Published on 03/11/2026 at 07:00, 4 hours 53 minutes ago

TINC publishes excellent results with a record investment year as the basis for future profit growth
Published on 03/11/2026 at 07:00, 4 hours 53 minutes ago

TINC publiceert voortreffelijke resultaten en legt met een record investeringsjaar de basis voor toekomstige winstgroei

View all LES ECHOS COMFI WIRE